Trending menu:
Rexgenero has opened the first site in the UK to enrol diabetic patients with chronic limb-threatening ischemia (CLI) for the Phase III SALAMANDER studies of REX-001.
Acadia Pharmaceuticals has reported that pimavanserin reduced the risk of psychosis relapse in dementia patients who participated in its Phase III HARMONY clinical trial.
Global contract research organisation PPD has added significant neuroscience and ethno-bridging expertise, expanding its early development research services for its clinical research units (CRUs).
BioXcel Therapeutics has announced plans to initiate two Phase III clinical trials of BXCL501 for the acute treatment of agitation in schizophrenia and bipolar disorder patients.
Ardelyx has reported positive top-line data from Phase III PHREEDOM clinical trial of tenapanor to treat hyperphosphatemia in chronic kidney disease (CKD) patients on dialysis.
Biogen has reported that the Phase II LILAC clinical trial of BIIB059 has met the primary endpoints in patients with cutaneous lupus erythematosus (CLE) and systemic lupus erythematosus (SLE).
Non-profit breast cancer organisation Metastatic Breast Cancer Alliance (MBCA) has released its MBC Connect 2.0 web-based registry to identify potential clinical trial matches for patients.
A Phase II clinical trial led by The Institute of Cancer Research (ICR) in London and The Royal Marsden NHS Foundation Trust has shown that AstraZeneca’s olaparib could improve survival...
INmune Bio has commenced the dosing of patients in a Phase Ib clinical trial of XPro1595 being conducted to help treat Alzheimer's disease.
Drug discovery and development firm Knopp Biosciences has said that it will start trial enrolment of dexpramipexole in severe eosinophilic asthma in the first half of 2020.
